Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.38 |
| ▸ | APLNR | P35414 | 1/20 | 0.35 |
| ▸ | CCR1 | P32246 | 2/20 | 0.33 |
| ▸ | CCR5 | P51681 | 2/20 | 0.33 |
| ▸ | CCR8 | P51685 | 2/20 | 0.33 |
| ▸ | MGMT | P16455 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | NOS3 | P29474 | 2/20 | 0.32 |
| ▸ | NOS2 | P35228 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | BTK | Q06187 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | PLAU | P00749 | 1/20 | 0.32 |
| ▸ | ELANE | P08246 | 1/20 | 0.31 |
| ▸ | AURKA | O14965 | 1/20 | 0.31 |
| ▸ | TTK | P33981 | 1/20 | 0.31 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18811973 | 0.79 | PLAU (0.38) | CCNA2CDK2CCNA1APLNRCCR1 | |
| SCHEMBL6792963 | 0.73 | NOS3 (0.48) | APLNRCCR1CCR5CCR8NOS3 | |
| SCHEMBL21567478 | 0.72 | CCR1 (0.35) | CCR1CCR5CCR8MAPTNOS3 | |
| SCHEMBL12051932 | 0.72 | MAPT (0.36) | CCR1CCR5CCR8MAPTNOS3 | |
| SCHEMBL12528205 | 0.72 | NOS2 (0.54) | CCNA2CDK2CCNA1CCR1CCR5 | |
| SCHEMBL12051931 | 0.72 | RXFP1 (0.36) | CCR1CCR5CCR8MAPTNOS3 | |
| SCHEMBL23624004 | 0.71 | CCR1 (0.38) | APLNRCCR1CCR5CCR8NOS3 | |
| SCHEMBL26361648 | 0.71 | MAOA (0.41) | APLNRCCR1CCR5CCR8NOS3 | |
| SCHEMBL5942324 | 0.69 | DRD1 (0.39) | APLNRCCR1CCR5CCR8MAPT | |
| SCHEMBL24457916 | 0.69 | CCR1 (0.37) | APLNRCCR1CCR5CCR8MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10258603-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-04-16 | — | — | US | disclosed |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
| US-20120183563-A1 | IMINOTHIADIAZINE DIOXIDE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS AND THEIR USE | MERCK SHARP & DOHME LLC | 2012-07-19 | — | — | US | disclosed |
| US-20110311516-A1 | Chemically Programmed Vaccination | THE SCRIPPS RESEARCH INSTITUTE (US) | 2011-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120183563-A1 | IMINOTHIADIAZINE DIOXIDE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS AND THEIR USE | BACE1, BACE2, APP | CCNA2 358/4885CDK2 85/4885CCNA1 115/4885 |
| US-20110311516-A1 | Chemically Programmed Vaccination | CD69, CD4, ICOS | CCNA2 3294/4885CDK2 2642/4885CCNA1 3976/4885 |
| US-10258603-B2 | Therapeutic compounds and uses thereof | BRD4, BRDT, BRD3 | CCNA2 1552/4885CDK2 782/4885CCNA1 1065/4885 |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | BRD4, BRDT, BRD3 | CCNA2 1552/4885CDK2 782/4885CCNA1 1065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.